science
J. Craig Venter Dies at 79
J. Craig Venter, who helped decode the human genome, has died at age 79. The FDA appointed an acting head for its biologics center and approved a new Alzheimer's drug. A biotech entrepreneur is launching an effort to scale bespoke medicines.
May 1, 3:29 PM·1m read2 sources
White House photographer / Wikimedia (Public domain)Audio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
J. Craig Venter, a scientist known for decoding the human genome, died at 79. He introduced speed and competition to genomics research. Multiple sources reported his passing and reflected on his contributions to biotechnology. The New York Times described Venter as a risk-taking outsider who brought controversy to one of science's biggest races.
The agency continues to search for a permanent leader. This follows the departure of Vinay Prasad's acting replacement context mentioned in reports. The approval was announced in biotech newsletters.
Vitarello is starting a new effort to scale bespoke medicines. This comes after her first startup faced challenges. Her daughter received a bespoke medicine previously. Matt Herper reflected on Venter's legacy, noting his vision shaped modern biotech.
Venter's work in genomics pioneered advancements in the field. Sources highlighted his relentless approach and impact on biotechnology. STAT reported on his contributions in a memorial piece.
“Remembering J. Craig Venter: a relentless scientist who changed biotech — and was all too easily misunderstood.”
Other biotech news included a five-way obesity drug showing effectiveness in mice. Akeso's survival data was discussed in a scorecard. The developments occur amid ongoing biotech innovations. Sources covered politics and research driving the industry. STAT's newsletter summarized these events for subscribers. The coverage emphasized science, politics, and money in biotech.
